Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Amsterdam – this weekend it’s time to showcase some important updates in hematology from the European Hematology Association (EHA).

It’s really hard not to like continental Europe when you see scenes like this from a major conference:

T cell lymphomas is not a topic we cover very often but it looks like it will receive attention here three times in a month with news from Corvus at ASCO and now an update on the intriguing story on CXCL12-positive AML and PTCL from Kura Oncology.

We’ve been following the latter story for a while now and after the previous looks at the rationale behind the translational data, it’s now time to explore what happens in clinical practice from their ongoing phase 2 clinical trial…

To learn more and get a heads up on our latest oncology insights and conference analysis, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Corvus Pharmaceuticals LogoA biotech company we’ve been following for several years – on what has turned out to be a rollercoaster ride so far – is Corvus Pharmaceuticals (NASDAQ: CRVS).

They were pioneers in targeting the adenosine pathway with their adenosine A2A receptor antagonist,  CPI–444, now known as ciforadenant.

So what’s new at Corvus? It turns out quite a lot.

At ASCO 2019, BSB caught up with Richard A Miller MD, Co-Founder, President, and CEO of Corvus Pharmaceuticals to learn more about their progress and importantly, where they’re headed.

To learn more and get a heads up on our latest oncology insights and conference analysis, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

In wave 3 of the immuno-oncology surge things have slowed down, partly due to a raft of combination trials yet to read out and partly because the reality has finally hit that tumour heterogeneity means there will be variable patient responses.

Just getting from room to room on time can be a real challenge with 40,000 other people present!

This complexity can come about in many forms… immunosuppression, alterations in gene functions, resistance and immune escape, to name a few.

If we want to help more people respond to these therapies then before we can rush headlong into another round of combination trials, we first have to go back to looking carefully at the underlying biology of the diseases and listen to what the patient’s tumours are telling us in order to fix things.

To accomplish this feat requires considerable time, energy, effort, and a lot of bioinformatics.

In this post we explore five key talks that highlight different aspects of biomarkers of response and mechanisms of resistance.  From there, we may see additional validation and prospective testing to determine how best to segment people so that they have the greatest chance of responding to the therapy administered.

One thing that most people don’t have these days is time, which is how we can help you because here’s a handy short cut to finding out more about five complex and diverse areas on biomarkers or IO resistance quickly and easily…

To learn more and get a heads up on our latest oncology insights and conference analysis, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Chicago – Having stayed until the last morning of the last day for a final expert interview and sessions on CAR-T therapy and metastatic breast cancer, there were certainly some interesting targets and findings to discuss in the post meeting analysis.

I particularly wanted to post some thoughts and commentary on the ongoing Macrogenics story around margetuximab, an anti-HER2 antibody that binds with elevated affinity to both the lower and higher affinity forms of CD16A, an Fc receptor.

In our last review in February, we noted that the company “could miss on PFS and have to wait for OS down the road,” which wasn’t far off given the rather weak PFS benefit of 0.9 months announced on May 15th.

We finally got to see the initial SOPHIA data presented at ASCO this morning by Dr Hope Rugo (UCSF), so what did we learn?

To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Chicago – here we are with highlights and insights from Day 4 of #ASCO19 and time is running down on this meeting with just half a day to go – whew!

One of the highlights of medical and scientific meetings we go to is meeting early career researchers, especially those who are doing translational research.

On Monday at ASCO19 we particularly enjoyed talking with Dr Wungi Park (@W_Park_MD) from Memorial Sloan Kettering Cancer Center who presented a poster on homologous recombination deficiency (HRD) as a biomarker in pancreatic cancer (abstract 4132).

We look forward to hearing more from him and colleagues as data is generated from the clinical trial they plan to start later in this year to investigate this further. Translational research in action!

What were some of our other highlights of Manic Monday at ASCO19? We’ve shared a few in the post below for BSB subs.

To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Chicago: We’ve heard a lot of people say how they think this year’s annual meeting ASCO19 is not as good for data as previous years, and we’re going to have to respectfully disagree.

On Sunday at ASCO19 there was a wealth of data on display in multiple sessions with some noticeable “winners and losers” when it comes to drugs in development.

Dr Hedy Kindler presents phase III POLO trial in Plenary Session at ASCO19. Data simultaneously published in NEJM.

In this post, we’ve some top-line commentary on some of the Sunday sessions we covered, and what caught our attention. As always our detailed analysis comes after the meeting in the “post-game” show.

To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Chicago – the 2019 ASCO annual meeting is in full swing and it’s plenary Sunday where the jewels in the crown are presented.

Noteworthy this year is the olaparib data being presented by Dr Hedy Kindler.

In this post, we’ve commentary on the data we’ve heard so far, highlights from yesterday’s sessions, and what you can expect to hear today if you’re in Chicago for Plenary Sunday.

To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

The 2019 annual meeting of the American Society of Clinical Oncology (Twitter #ASCO19) is now in full swing, and we’re kicking off our on-site meeting coverage with a review of the some of the highlights of Friday here in Chicago.

In today’s Daily Highlights we offer seven areas of interest and offer commentary on the insights gleaned from the data that is rolling out so far…

To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Chinatown Chicago

One of the things we try to do on BSB is tread paths that aren’t well travelled.

It’s a bit like coming to Chicago and visiting areas such as Chinatown that are beyond the common tourist sights. It can take a bit of effort, but often delivers a memorable experience in the process.

In this final preview of #ASCO19 before the educational sessions start tomorrow, we’re offering up 10 abstracts that we think are underrated and noteworthy of closer attention.

Like any guide book our recommendations are subjective, but if you’d like to read more then subscribers can login or you can purchase access.

To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Bispecifics in the garden? Who knows!

We’re continuing our preview of the ASCO 2019 annual meeting (Twitter #ASCO19) with a look at a fast-paced area of drug development that is attracting a lot of interest, namely the potential of bispecifics as novel cancer treatments.

On BSB we’ve been following this emerging field for the past five years or so, but at this year’s ASCO we expect to hear clinical data that may offer new insights.

If you’ve been in London this past week, then you may have been at the annual Royal Horticultural Society (RHS) Chelsea Flower Show, which features impressively designed show gardens built around a theme or location. They’re built with great attention to detail just for Chelsea, then at a few days they’re dismantled.

Large cancer meetings like ASCO19 are a bit like that too. We all come together for a few days to mix and mingle then go our separate ways again.

In the spirt of Chelsea, in this post we’re taking a look at what to watch for in the “ASCO19 bispecific garden,” if one were to be made.  There’s certainly a surfeit of choice to consider and like flowers, some may flourish under certain conditions, but not others.

To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Sign Up for New Post Alerts
error: Content is protected !!